Home / Resource Library / Long-term three-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesLong-term three-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies